Following the centralised process of achieving regulatory approval, orphan drugs are subject to individual National scrutiny when it comes to gaining reimbursement. With the ultimate loser being the rare disease patient in need, all European member states are to deliver Rare Disease Plans by 2013 in order to create a uniform and normalised access to healthcare.
Segolene Ayme, Director of Research at INSERM and chair of the EU Committee of Experts on Rare Diseases will present on how the member states are prioritising best practice for tackling rare diseases. The intention is to transform Europe into a leading patient-orientated environment through the National Rare Disease Plans.
Discover the objectives of national rare disease policy makers at the World Orphan Drug Congress 2011 in Geneva on the 29th November – 1st December. Register now and book early to take advantage of our biggest discounts